Clinical update of opioid agonist and partial agonist medications for the maintenance treatment of opioid addiction

Seminars in the Neurosciences

Volumn 9, Issue 3-4, 1997, Pages 140-157

  Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Buprenorphine; Dynorphin; LAAM; Methadone; Opioid agonist; Partial agonist

Indexed keywords

ACETYLMETHADOL; BUPRENORPHINE; DYNORPHIN A; KAPPA OPIATE RECEPTOR AGONIST; METHADONE; MU OPIATE RECEPTOR; OPIATE AGONIST; PARTIAL AGONIST;

CLINICAL TRIAL; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG SAFETY; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH CARE; META ANALYSIS; METHADONE TREATMENT; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PATIENT COUNSELING; REVIEW;

EID: 0030671238     PISSN: 10445765     EISSN: None     Source Type: Journal    
DOI: 10.1006/smns.1997.0114     Document Type: Article

References (125)

1. 1. Kreek, M. J. (1975) Pharmacologic modalities of therapy: Methadone maintenance and the use of narcotic antagonists. In Heroin Dependency: Medical, Economic and Social Aspects (B. Stimmel, Ed.), pp. 232-290 Stratton Intercontinental Medical Book Corp, New York.
2. 2. Cooper, J. R., Altman, F., Brown, B. S., and Czechowicz, D., Eds. (1983) Health consequences associated with use of methadone. In Research in the Treatment of Narcotic Addiction: State of the Art National Institute on Drug Abuse Monograph, DHHS Pub. (ADM) 83-1281.
3. 3. Hartman, N., and Kreek, M. J. (1983) Narcotic poisoning. In Current Therapy, pp. 896-898.
4. 4. Kreek, M. J. (1991) Using methadone effectively: Achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs. In Improving Drug Abuse Treatment: National Institute of Drug Abuse Research Monograph Series 106 (R. Pickens, C. Leukefeld, and C. R. Schuster, Eds.), pp. 245-266. Supt. of Docs., U.S. Govt. Print. Off., Washington, DC.
5. 5. Kreek, M. J. (1992) Rationale for maintenance pharmacotherapy of opiate dependence. In Addictive States (C. P. O'Brien and J. H. Jaffe, Eds.), pp. 205-230 Raven Press, New York.
6. 6. Kreek, M. J. (1992) Epilogue: Medical Maintenance Treatment for Heroin Addiction, from a Retrospective and Prospective Viewpoint. State Methadone Maintenance Treatment Guidelines Office for Treatment Improvement, Division for State Assistance November, 255-272.
7. 7. Wodak, A. (1994) Managing illicit drug use. Drugs 3, 446-457.
8. 8. Ling, W., Rawson, R. A., and Compton, M. A. (1994) Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine. J. Psychoactive Drugs 26(2), 119-128.
9. 9. Rettig, R. A., and Yarmolinsky, A., Eds. (1994) Federal Regulation of Methadone Treatment. National Academy of Sciences, National Academy Press, Washington, DC.
10. 10. Vocci, F., Chiang, C. N., Cummings, L., and Hawks, R. (1995) Overview: Medications development for the treatment of drug abuse. NIDA Res. Monogr. 149, 4-15.
11. 11. Kreek, M. J. (1996) Long-term pharmacotherapy for opiate (primarily heroin) addiction: Opiate Agonists. In Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach (C. R. Schuster, and M. J. Kuhar, Eds.), pp. 487-541. Springer-Verlag, Berlin.
12. 12. Kreek, M. J. (1996) Long-term pharmacotherapy for opiate (primarily heroin) addiction: Opiate antagonists and partial agonists. In Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach (C. R. Schuster, and M. J. Kuhar, Eds.), pp. 563-592. Springer-Verlag, Berlin.
13. 13. Kreek, M. J. (1996) Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity and in specific addictive diseases. J. Neurochem. Res. 21(11), 1469-1488.
14. 14. Dole, V. P., and Nyswander, M. E. (1965) A medical treatment for diacetylmorphine (heroin) addiction. J. Am. Med. Assoc. 193, 646-650.
15. 15. Dole, V. P., Nyswander, M. E., and Kreek, M. J. (1966) Narcotic blockade. Arch. Intern. Med. 118, 304-309.
16. 16. Kreek, M. J. (1972) Medical safety, side effects and toxicity of methadone. Proceedings of the Fourth National Conference on Methadone Treatment, NAPAN-NIMH, 171-174.
17. 17. Kreek, M. J., Dodes, L., Kane, S., Knobler, J., and Martin, R. (1972) Long-term methadone maintenance therapy: Effects on liver function. Ann. Intern. Med. 77, 598-602.
18. 18. Inturrisi, C. E., and Verebely, K. (1972) The levels of methadone in the plasma in methadone maintenance. Clin. Pharmacol. Ther. 13(5), 633-637.
19. 19. Kreek, M. J. (1973) Plasma and urine levels of methadone. NY State J. Med. 73, 2773-2777.
20. 20. Kreek, M. J. (1973) Physiological implications of methadone treatment. In Methadone Treatment Manual, pp. 85-91. U.S. Dept. of Justice (USGPO) 2700-00227, Washington, DC.
21. 21. Kreek, M. J. (1973) Medical safety and side effects of methadone in tolerant individuals. J. Am. Med. Assoc. 223, 665-668.
22. 22. Dole, V. P., and Kreek, M. J. (1973) Methadone plasma levels: Sustained by a reservoir of drug in tissue. Proc. Natl. Acad. Sci. USA 70, 10.
23. 23. Cushman, P., and Kreek, M. J. (1974) Methadone-maintained patients. Effects of methadone on plasma testosterone, FSH, LH and prolactin. NY State J. Med. 74, 1970-1973.
24. 24. Cushman, P., and Kreek, M. J. (1974) Some endocrinologic observations in narcotic addicts. In Narcotic and the Hypothalamus (E. Zimmerman, and R. George, Eds.), pp. 161-173. Raven Press, New York.
25. 25. Kreek, M. J., Garfield, J. W., Gurjahr, C. L., and Giusti, L. M. (1976) Rifampin-induced methadone withdrawal. N. Engl. J. Med. 294, 1104-1106.
26. 26. Kreek, M. J. (1978) Medical complications in methadone patients. Ann. NY Acad. Sci. 311, 110-134.
27. 27. Kreek, M. J., Hachey, D. L., and Klein, P. D. (1979) Stereoselective disposition of methadone in man. Life Sci. 24, 925-932.
28. 28. Kreek, M. J. (1979) Methadone disposition during the perinatal period in humans. Pharmacol. Biochem. Behav. II (Suppl), 1-7.
29. 29. Kreek, M. J. (1981) Metabolic interactions between opiates and alcohol. Ann. NY Acad. Sci. 362, 36-49.
30. 30. Kreek, M. J., Wardlaw, S. L., Friedman, J., Schneider, B., and Frantz, A. G. (1981) Effects of chronic exogenous opioid administration on levels of one endogenous opioid (beta-endorphin) in man. In Advances in Endogenous and Exogenous Opioids (E. Simon, and H. Takagi, Eds.), pp. 364-366. Kodansha Ltd. Publishers, Tokyo.
31. 8 methadone. J. Pharmacol. Sci. 71, 39-43.
32. 32. Kreek, M. J., and Hartman, N. (1982) Chronic use of opioids and antipsychotic drugs: Side effects, effects on endogenous opioids and toxicity. Ann. NY Acad. Sci. 398, 151-172.
33. 33. Kreek, M. J., Wardlaw, S. L., Hartman, N., Raghunath, J., Friedman, J., Schneider, B., and Frantz, A. G. (1983) Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 33, 409-411.
34. 34. Kreek, M. J., Raghunath, J., Plevy, S., Hamer, D., Schneider, B., and Hartman, N. (1984) ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5, 277-278.
35. 35. Pond, S. M., Kreek, M. J., Tong, T. G., Raghunath, J., and Benowitz, N. L. (1985) Altered methadone pharmacokinetics in methadone-maintained pregnant women. J. Pharmacol. Exp. Ther. 233, 1-6.
36. 36. Hanbury, R., Sturiano, V., Cohen, M., Stimmel, B., and Aguillaume, C. (1986) Cocaine use in persons on methadone maintenance. Adv. Alcohol Subst. Abuse 6, 97-106.
37. 37. Novick, D. M., Pascarelli, E. F., Joseph, H., Salsitz, E. A., Richman, B. L., Desjarlais, D. C., Andersen, N., Dole, V. P., and Nyswander, M. E. (1988) Methadone maintenance patients in general medical practice. J. Am. Med. Assoc. 259, 3299-3302.
38. 38. Novick, D. M., Ochshorn, M., Ghali, V., Croxson, T. S., Mercer, W. D., Chiorazzi, N., and Kreek, M. J. (1989) Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 250, 606-610.
39. 39. Kennedy, J. A., Hartman, N., Sbriglio, R., Khuri, E., and Kreek, M. J. (1990) Metyrapone-induced withdrawal symptoms. Brit. J. Addict. 85, 1133-1140.
40. 40. Ball, J. C., and Ross, A. (1991) The Effectiveness of Methadone Maintenance Treatment: Patients, Programs Services and Outcomes. Springer, Berlin/Heidelberg/New York.
41. 41. Culpepper-Morgan, J. A., Inturrisi, C. E., Portenoy, R. K., Foley, K., Houde, R. W., Marsh, F., and Kreek, M. J. (1992) Treatment of opioid induced constipation with oral naloxone: A pilot study. Clin. Pharmacol. Ther. 23, 90-95.
42. 42. Unterwald, E. M., Home-King, J., and Kreek, M. J. (1992) Chronic cocaine alters brain mu opioid receptors. Brain Res. 584, 314-318.
43. 43. Novick, D. M., Richman, B. L., Friedman, J. M., Friedman, J. E., Fried, C., Wilson, J. P., Townley, A., and Kreek, M. J. (1993) The medical status of methadone maintained patients in treatment for 11-18 years. Drug and Alcohol Dep. 33, 235-245.
44. 44. McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E., and O'Brien, C. P. (1993) The effects of psychosocial services in substance abuse treatment. J. Am. Med. Assoc. 269(15), 1953-1959.
45. 45. Unterwald, E. M., Rubenfeld, J. M., and Kreek, M. J. (1994) Repeated cocaine administration upregulates kappa and mu, but not delta opioid receptors. NeuroReport 5, 1613-1616.
46. 46. Borg, L., Broe, D. M., Ho, A., and Kreek, M. J. (1995) Cocaine abuse is decreased with effective methadone maintenance treatment at an urban Department of Veterans Affairs (DVA) Program. In Problems of Drug Dependence 1994, Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph Series 153 (L. S. Harris, Ed.), pp. 17. Supt. of Docs., U.S. Govt. Print. Off., DDHS Pub. No. (ADM)95-3883, Washington, DC.
47. 47. Zhou, Y., Spangler, R., Maggos, C. E., LaForge, K. S., Ho, A., and Kreek, M. J. (1996) Steady-state methadone in rats does not change mRNA levels of cortisotropin-releasing factor, its pituitary receptor or poopiomelanocortin. Eur. J. Pharmacol. 315, 31-35.
48. 48. Zhou, Y., Spanger, R., LaForge, K. S., Maggos, C. E., Ho, A., and Kreek, M. J. (1996) Corticotropin-releasing factor and CRF-R1 mRNAs in rat brain and pituitary during "binge" pattern cocaine administration and chronic withdrawal. J. Pharmacol. Exp. Ther. 279, 351-358.
49. 49. Kreek, M. J. (1996) Opiates, opioids and addiction. Mol. Psych. 1, 232-254.
50. 50. Zubieta, J.-K., Gorelick, D. A., Stauffer, R., Ravert, H. T., Dannals, R. F., and Frost, J. J. (1996) Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nature Med. 2(11), 1225-1229.
51. 51. Culpepper-Morgan, J. A., and Kreek, M. J. (1997) HPA axis hypersensitivity to naloxone in opioid dependence: A case of naloxone induced withdrawal. Metabolism 46, 130-134.
52. 52. Des Jarlais, D. C., Marmor, M., Cohen, H., Yancovitz, S., Garber, J., Friedman, S., Kreek, M. J., Miescher, A., Khuri, E., Friedman, S. M., Rothenberg, R., Echenberg, D., O'Malley, P. O., Braff, E., Chin, J., Burtenol, P., and Sikes, R. K. (1984) Antibodies to a retrovirus etiologically associated with Acquired Immunodeficiency Syndrome (AIDS) in populations with increased incidences of the syndrome. MMWR 33, 377-379.
53. 53. Novick, D., Kreek, M. J., Des Jarlais, D., Spira, T. J., Khuri, E. T., Raghunath, J., Kalyanaraman, V. S., Gelb, A. M., and Miescher, A. (1986) Antibody to LAV, the putative agent of AIDS, in parenteral drug abusers and methadone-maintained patients: Abstract of clinical research findings: Therapeutic, historical, and ethical aspects. In Problems of Drug Dependence, 1985; Proceedings of the 47th Annual Scientific Meeting of The Committee on Problems of Drug Dependence ( L. S. Harris, Ed.), pp. 318-320. NIDA Research Monograph Series 67, Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM)86-1448, Washington, DC.
54. 54. Novick, D. M., Khan, I., and Kreek, M. J. (1986) Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. United Nations Bulletin on Narcotics 38, 15-25.
55. 55. Novick, D. M., Trigg, H. L., Des Jarlais, D. C., Friedman, S. R., Vlahov, D., and Kreek, M. J. (1989) Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J. Med. Virol. 29, 181-185.
56. 56. Chaisson, R. E., Bacchetti, P., Osmond, D., Brodie, B., Sande, M. A., and Moss, A. R. (1989) Cocaine use and HIV infection in intravenous drug users in San Francisco. J. Am. Med. Assoc. 261, 561-565.
57. 57. Des Jarlais, D. C., Friedman, S. R., Novick, D. M., Sotheran, J. L., Thomas, P., Yancovitz, S. R., Mildvan, D., Weber, J., Kreek, M. J., Maslansky, R., Bartelme, S., Spira, T., and Marmor, M. (1989) HIV-1 infection among intravenous drug users in Manhattan, New York City 1977 to 1987. J. Am. Med. Assoc. 261, 1008-1012.
58. 58. Kreek, M. J., Des Jarlais, D. C., Trepo, C. L., Novick, D. M., Abdul-Quader, A., and Raghunath, J. (1990) Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. J. Infect. Dis. 162, 538-541.
59. 59. Schwartz, E. L., Brechbuhl, A.-B., Kahl, P., Miller, M. A., Selwyn, P. A., and Friedland, G. H. (1992) Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J. Acquired Immune Defic. Syd. 5, 619-626.
60. 60. Metzger, D. S., Woody, G. E., McLellan, T. A., O'Brien, C. P., Druley, P., Navaline, H., DePhilippis, D., Stolley, P., and Abrutyn, E. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: An 18-month prospective follow-up. J. Acquired Immune Defic. Syndr. 6, 1049-1056.
61. 61. Borg, L., and Kreek, M. J. (1995) Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-positive and AIDS patients. Curr. Opin. Psychiatr. 8, 199-202.
62. 62. Jaffe, J. H., Schuster, C. R., Smith, B. B., and Blachly, P. H. (1970) Comparison of acetylmethadol and methadone in the treatment of long-term heroin users. J. Am. Med. Assoc. 211, 1834-1836.
63. 63. Jaffe, J. H., and Senay, E. C. (1971) Methadone and L-methadyl acetate: Use in management of narcotic addicts. J. Am. Med. Assoc. 216(8), 1303-1305.
64. 64. Jaffe, J. H., Senay, E. C., Schuster, C. R., Renault, P. R., Smith, B., and DiMenza, S. (1972) Methadyl acetate v. methadone: A double-blind study in heroin users. J. Am. Med. Assoc. 222(4), 437-442.
65. 65. Zaks, A., Fink, M., and Freedman, A. M. (1972) Levomethadyl in maintenance treatment of opiate dependence. J. Am. Med. Assoc. 220(6), 811-813.
66. 66. Ling, W., Charuvastra, V. C., and Klett, C. J. (1975) Current status of the evaluation of LAAM as a maintenance drug for heroin addicts. Am. J. Drug Alcohol Abstr. 2(3-4), 307-315.
67. 67. Blaine, J. D., Renault, P., Eds. (1976) RX 3× a week LAAM: Alternative to methadone. DHEW-NIDA Research Monograph, Series 8, Rockville, MD.
68. 68. Ling, W., Charuvastra, C., Kaim, S. C., and Klett, C. J. (1976) Methadyl acetate and methadone as maintenance treatments for heroin addicts: A Veterans Administration cooperative study. Arch. Gen. Psych. 33(6), 709-720.
69. 69. Mendelson, J. H., Inturrisi, C. E., Renault, P., and Senay, E. C. (1976) Effects of acetylmethadol on plasma testosterone. Clin. Pharmacol. Ther. 19(3), 371-374.
70. 70. Gevert, P., Masover, B., and Goldstein, A. (1977) Failure of methadone and levomethadyl acetate (Levo-alpha-acetylmethadol) maintenance to affect memory. Arch. Gen. Psych. 34, 849-853.
71. 71. Blaine, J. D., Renault, P., Levine, G. L., and Whysner, J. A. (1978) Clinical use of LAAM. Ann. NY Acad. Sci. 311, 214-231.
72. 72. Crowley, T. J., Jones, R. H., Hydinger-Macdonald, M. J., Lingle, J. R., Wagner, J. E., and Egan, D. J. (1979) Every-other-day acetylmethadol disturbs circadian cycles of human motility. Psychopharmacology (Berlin) 62, 151-155.
73. 73. Judson, B. A., and Goldstein, A. (1979) Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts I. Dosage schedule for induction and stabilization. Drug Alcohol Dep. 4(6), 461-466.
74. 74. Judson, B. A., and Goldstein, A. (1982) Symptom complaints of patients maintained on methadone, LAAM (methadyl acetate), and naltrexone at different times in their addiction careers. Drug Alcohol Dep. 10(2-3), 269-282.
75. 75. Mendelson, J. H., Ellingboe, J., Judson, B. A., and Goldstein, A. (1984) Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal. Clin. Pharmacol. Ther. 15(4), 545-547.
76. 76. Orlaam Drug Information (1993) Levomethadyl acetate hydrochloride oral solution. 1-10. [Package insert].
77. 77. Abramowic, M. (1994) LAAM: A long-acting methadone for treatment of heroin addiction. Med. Lett. 36(924), 52.
78. 78. Prendergast, M. L., Grella, C., Perry, S. M., and Anglin, M. D. (1995) Levo-alpha-acetylmethadol (LAAM): Clinical, research, and policy issues of a new pharmacotherapy for opioid addiction. J. Psychoactive Drugs 27(3), 239-247.
79. 79. Lewis, J. W., and Readhead, M. J. (1970) Novel analgetics and molecular rearrangements in morphine-thebaine group XVIII 3-deoxy-6,14-endo-etheno-6,7,8,14-tetrahydrooripavines. J. Med. Chem. 13, 525-527.
80. 80. Cowan, A., Lewis, J. W., and Macfarlane, I. R. (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60, 537-545.
81. 81. Jasinski, D. R., Pevnick, J. S., and Griffith, J. D. (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psych. 35, 501-516.
82. 82. Heel, R. C., Brogden, R. N., Speight, T. M., and Avery, G. S. (1979) Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 17, 81-110.
83. 83. McQuay, H. J., Bullingham, R. E. S., Paterson, G. M. C., and Moore, R. A. (1980) Clinical effects of buprenorphine during and after operation. Br. J. Anaesth. 52, 1013-1019.
84. 84. Mello, N. K., and Mendelson, J. H. (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207, 657-659.
85. 85. Mello, N. K., Mendelson, J. M., and Kuehnle, J. C. (1982) Buprenorphine effects on human heroin self-administration: An operate analysis. J. Pharmacol. Exp. Ther. 223, 30-39.
86. 86. Mendelson, J. H., Ellingboe, J., Mello, N. K., and Kuehnle, J. (1982) Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. J. Pharmacol. Exp. Ther. 220, 252-255.
87. 87. Bullingham, R. E. S., McQuay, H. J., and Moore, R. A. (1983) Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin. Pharmacol. 8, 332-343.
88. 88. Cone, E. J., Gorodetzky, C. W., Yousefnejad, D., Buchwald, W. F., and Johnson, R. E. (1984) The metabolism and excretion of buprenorphine in humans. Drug Met. Disp. 12(5), 577-581.
89. 89. Reisinger, M. (1985) Buprenorphine as new treatment for heroin dependence. Drug Alcohol Dep. 16, 257-262.
90. 90. Lehmann, K. A., Reichling, U., and Wirtz, R. (1988) Influence of naloxone on the postoperative analgesic and respiratory effects of buprenorphine. Eur. J. Clin. Pharmacol. 34, 343-352.
91. 91. Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., and Johnson, R. E. (1988) Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther. 247, 47-53.
92. 92. Weinberg, D. S., Inturrisi, C. E., Reidenberg, B., Moulin, D. E., Nip, T. J., Wallenstein, S., Houde, R. W., and Foley, K. M. (1988) Sublingual absorption of selected opioid analgesics. Clin. Pharmacol. Ther. 44, 335-342.
93. 93. Johnson, R. E., Cone, E. J., Henningfield, J. E., and Fudala, P. J. (1989) Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin. Pharmacol. Ther. 46, 335-343.
94. 94. Kosten, T. R., Kleber, H. D., and Morgan, C. (1989) Treatment of cocaine abuse with buprenorphine. Biol. Psych. 26, 170-172.
95. 95. Mendelson, J. H., Mello, N. K., Teoh, S. K., Lloyd-Jones, J. G., and Clifford, J. M. (1989) Naloxone suppresses buprenorphine stimulation of plasma prolactin. J. Clin. Psychopharmacol. 9(2), 105-109.
96. 96. Fudala, P. J., Jaffe, J. H., Dax, E. M., and Johnson, R. E. (1990) Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin. Pharmacol. Ther. 47, 525-534.
97. 97. Kosten, T. R., Morgan, C., and Kreek, M. J. (1992) Beta-endorphin levels during heroin, methadone, buprenorphine and naloxone challenges: Preliminary findings. Biol. Psych. 32, 523-528.
98. 98. Kosten, T. R., Rosen, M. I., Schottenfeld, R., and Ziedonis, D. (1992) Buprenorphine for cocaine and opiate dependence. Psychopharmacol. Bull. 28(1), 15-19.
99. 99. Blaine, J. D. (1992) Introduction (to Buprenorphine: An alternative treatment for opioid dependence). NIDA Res. Monogr. 121, 1-4.
100. 100. Johnson, R. E., Jaffe, J. H., and Fudala, P. J. (1992) A controlled trial of buprenorphine treatment for opioid dependence. J. Am. Med. Assoc. 267, 2750-2755.
101. 101. Kosten, T. R., Schottenfeld, R., Ziedonis, D., and Falcioni, J. (1993) Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181(6), 358-364.
102. 102. Mendelson, J., Jones, R. T., Fernandez, I., Welm, S., Melby, A. K., and Baggott, M. J. (1996) Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin. Pharmacol. Ther. 60(1), 105-114.
103. 103. Ling, W., Wesson, D. R., Charuvastra, C., and Klett, J. C. (1996) A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatr. 53, 401-407.
104. 104. Goldstein, A., Tachibana, S., Lowney, L. I., Hunkapiller, M., and Hood, L. (1979) Dynorphin(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. USA 145, 267-272.
105. 105. Chavkin, C., and Goldstein, A. (1982) Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215, 413-415.
106. 106. Aceto, M. D., Dewey, W. L., Chang, L. J., and Lee, N. M. (1982) Dynorphin(1-13) effects in nontolerant and morphine-dependent rhesus monkeys. Eur. J. Pharmacol. 83, 139-142.
107. 107. Wen, H. L., and Ho, W. K. K. (1982) Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur. J. Pharmacol. 82, 183-186.
108. 108. Young, E. A., Walker, J. M., Houghten, R., and Akil, H. (1987) The degradation of dynorphin A in brain tissue in vivo and in vitro. Peptides 8, 701-707.
109. 109. Green, P. G., and Lee, N. M. (1988) Dynorphin A(1-13) attenuates withdrawal in morphine-dependent rats: Effect of route of administration. Eur. J. Pharmacol. 145, 267-272.
110. 110. Takemori, A. E., Loh, H. H., and Lee, N. M. (1992) Suppression by dynorphin A(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur. J. Pharmacol. 221, 223-226.
111. 111. Chou, J. Z., Pinto, S., Kreek, M. J., and Chait, B. T. (1993) Study of opioid peptides by laser desorption mass spectrometry. In Problems of Drug Dependence, 1992, Proceedings of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series 132 (L. S. Harris, Ed.), pp. 380. Supt. of Docs., U.S. Govt. Print. Off., DHHS Pub. No. (ADM) 93-3505, Washington, DC.
112. 112. Takemori, A. E., Loh, H. H., and Lee, N. M. (1993) Suppression by dynorphin A and (Des-Tyr) dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266, 121-124.
113. 1-13 administration causes elevation of serum levels of prolactin in human subjects. In Problems of Drug Dependence, 1993, Proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series 141 (L. S. Harris, Ed.), pp. 108. Supt. of Docs., U.S. Govt. Print. Off., NIH Pub. No. 94-3749, Washington, DC.
114. 114. Chou, J. Z., Kreek, M. J., and Chait, B. T. (1994) Matrix-assisted laser desorption mass spectrometry of biotransformation products of dynorphin A in vitro. J. Am. Soc. Mass Spectrom. 5, 10-16.
115. 115. Uneklabh, T., Wessagowit, V., Sintavanarong, P., and Lukanapichonchut, L. (1995) Clinical effect of dynorphin on heroin addicts. J. Med. Assoc. Thai. 78(10), 509-516.
116. 116. Hooke, L. P., He, L., and Lee, N. M. (1995) Dynorphin A modulates acute and chronic opioid effects. J. Pharmacol. Exp. Ther. 273, 292-297.
117. 2-17 inhibit adenylyl cyclase activity in rat caudate putamen. J. Pharmacol. Exp. Ther. 277, 359-365.
118. 1-13 peptides in human blood, ex vivo. Peptides 17(6) , 983-990.
119. 1-17 is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass spectrometry. J. Pharmacol. Exp. Ther. 279, 507-514.
120. 120. Ingham, J. M., Cherny, N. I., Tiseo, P. J., Caraceni, A., Lapin, J., Inturrisi, C., Goldblum, R., Johnson, J. H., Kreek, M. J., Foley, K. M., and Portenoy, R. K. (1996) A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Dynorphin A (1-13) in Opioid-Treated Patients with Chronic Pain. Abstract for 8th World Congress on Pain.
121. 121. Yu, J., Chait, B. T., Toll, L., and Kree, M. J. (1996) Nociceptin in vitro biotransformation in human blood. Peptides 17, 873-876.
122. 122. Yu, J., Butelman, E. R., Woods, J. H., Chait, B. T., and Kreek, M. J. (1997) Dynorphin A(1-8) analog, E-2078, is stable in human and rhesus monkey blood. J. Pharmacol. Exp. Ther. 280, 1147-1151.
123. 1-17 reduces extracellular dopamine levels in the nucleus accumbens. In Problems of Drug Dependence, 1996, Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series (L. S. Harris, Ed.). Supt. of Docs., U.S. Govt. Print. Off., Washington, DC, in press.
124. 124. Specker, S., Wananukul, W., Nolin, K., Hatsukami, D., and Pentel, P. (1997) Effects of dynorphin on opiate addiction in humans. In Problems of Drug Dependence, 1996, Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series (L. S. Harris, Ed.), Supt of Docs, US Govt Print Off, Washington, DC, in press.
125. 125. Borg, L., Schluger, J., Maniar, N., Porter, M., Gunduz, M., Ho, A., and Kreek, M. J. (1998) Dynorphin A(1-13) elevates serum prolactin levels by an opioid receptor mechanism:controlled studies of normal volunteers. In Problems of Drug Dependence, 1997, Proceedings of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series (L. S. Harris, Ed.). Supt of Docs, US Govt Print Off, Washington, DC, in press.